These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 7117370)

  • 21. A 5-hydroxytryptamine-like mode of anorectic action for 6-chloro-2-[1-piperazinyl]-pyrazine (MK-212).
    Clineschmidt BV; McGuffin JC; Pflueger AB; Totaro JA
    Br J Pharmacol; 1978 Apr; 62(4):579-89. PubMed ID: 656703
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antagonism of 5-hydroxytryptamine receptors by quipazine.
    Lansdown MJ; Nash HL; Preston PR; Wallis DI; Williams RG
    Br J Pharmacol; 1980 Mar; 68(3):525-32. PubMed ID: 7052342
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anorexia and brain serotonin: development of tolerance to the effects of fenfluramine and quipazine in rats with serotonin-depleting lesions.
    Carlton J; Rowland N
    Pharmacol Biochem Behav; 1984 May; 20(5):739-45. PubMed ID: 6610879
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of metergoline and other serotonin receptor antagonists on serum corticosterone in rats.
    Fuller RW; Snoddy HD
    Endocrinology; 1979 Oct; 105(4):923-8. PubMed ID: 477605
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evidence that serotonin receptors are involved in the anticonvulsant effect of yohimbine in mice.
    Ludvig N; György L; Vizi ES
    Psychopharmacology (Berl); 1986; 88(1):82-5. PubMed ID: 2868485
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Further studies of serotonergic activity in the regulation of the cold stimulated thyrotropin secretion in male rats.
    Männistö PT; Tuominen RK
    Pharmacol Toxicol; 1988 Aug; 63(2):65-9. PubMed ID: 3186622
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A behavioural and biochemical study in rats of 5-hydroxytryptamine receptor agonists and antagonists, with observations on structure-activity requirements for the agonists.
    Green AR; Hall JE; Rees AR
    Br J Pharmacol; 1981 Jul; 73(3):703-19. PubMed ID: 6166345
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serotonin and the mammalian circadian system: I. In vitro phase shifts by serotonergic agonists and antagonists.
    Prosser RA; Dean RR; Edgar DM; Heller HC; Miller JD
    J Biol Rhythms; 1993; 8(1):1-16. PubMed ID: 8490207
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of quipazine and methysergide on play in juvenile rats.
    Normansell L; Panksepp J
    Pharmacol Biochem Behav; 1985 May; 22(5):885-7. PubMed ID: 2989950
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quipazine reduces food intake in the rat by activation of 5-HT2-receptors.
    Hewson G; Leighton GE; Hill RG; Hughes J
    Br J Pharmacol; 1988 Oct; 95(2):598-604. PubMed ID: 2906561
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ketanserin-sensitive depressant actions of 5-HT receptor agonists in the neonatal rat spinal cord.
    Manuel NA; Wallis DI; Crick H
    Br J Pharmacol; 1995 Nov; 116(6):2647-54. PubMed ID: 8590984
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of midbrain raphe lesion or 5,7-dihydroxytryptamine treatment on the prolactin-releasing action of quipazine and D-fenfluramine in rats.
    Quattrone A; Schettini G; di Renzo G; Tedeschi G; Preziosi P
    Brain Res; 1979 Sep; 174(1):71-9. PubMed ID: 487124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Presynaptic activation of the spinal serotonergic system in the rat by phencyclidine in vitro.
    Ohno Y; Warnick JE
    J Pharmacol Exp Ther; 1989 Jul; 250(1):177-83. PubMed ID: 2746496
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Involvement of 5-HT2A receptors in the elevation of rat serum corticosterone concentrations by quipazine and MK-212.
    Hemrick-Luecke SK; Fuller RW
    Eur J Pharmacol; 1996 Sep; 311(2-3):207-11. PubMed ID: 8891601
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Direct excitation of rat spinal motoneurones by serotonin.
    Takahashi T; Berger AJ
    J Physiol; 1990 Apr; 423():63-76. PubMed ID: 1696989
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potentiation in phencyclidine-induced serotonin-mediated behaviors after intracerebroventricular administration of 5,7-dihydroxytryptamine in rats.
    Nabeshima T; Yamaguchi K; Ishikawa K; Furukawa H; Kameyama T
    J Pharmacol Exp Ther; 1987 Dec; 243(3):1139-46. PubMed ID: 2826756
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The comparative roles of dopaminergic and serotonergic mechanisms in mediating quipazine induced increases in locomotor activity.
    Feigenbaum JJ; Yanai J; Klawans HL
    J Neural Transm; 1983; 57(1-2):27-37. PubMed ID: 6619829
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of the serotonin releasers 3,4-methylenedioxymethamphetamine (MDMA), 4-chloroamphetamine (PCA) and fenfluramine on acoustic and tactile startle reflexes in rats.
    Kehne JH; McCloskey TC; Taylor VL; Black CK; Fadayel GM; Schmidt CJ
    J Pharmacol Exp Ther; 1992 Jan; 260(1):78-89. PubMed ID: 1731054
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dopaminergic activity of quipazine.
    Schechter MD; Concannon JT
    Pharmacol Biochem Behav; 1982 Sep; 17(3):393-7. PubMed ID: 7146043
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of putative 5-hydroxytryptamine receptor active agents on D-amphetamine self-administration in controls and rats with 5,7-dihydroxytryptamine median forebrain bundle lesions.
    Leccese AP; Lyness WH
    Brain Res; 1984 Jun; 303(1):153-62. PubMed ID: 6610461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.